MSB 4.89% $1.07 mesoblast limited

Ann: Mesoblast Update on COVID-19 ARDS Trial, page-966

  1. 2,751 Posts.
    lightbulb Created with Sketch. 1849
    A question for you StanJupiter, in the aGVHD trials from memory there was only a few days between steroids use and REM-l application.
    In the new Ulcerative colitis trial they are fully flushing previous steroids.

    Are you suggesting that REM-l would be a first line treatment for aGVHD?

    Reg
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.